Literature DB >> 25409370

Glycemic control and excess mortality in type 1 diabetes.

Marcus Lind1, Ann-Marie Svensson, Mikhail Kosiborod, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Sofia Dahlqvist, Mark Clements, Annika Rosengren.   

Abstract

BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes.
METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality.
RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37).
CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25409370     DOI: 10.1056/NEJMoa1408214

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  234 in total

Review 1.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

2.  Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference.

Authors:  Mervi Andelin; Jort Kropff; Viktorija Matuleviciene; Jeffrey I Joseph; Stig Attvall; Elvar Theodorsson; Irl B Hirsch; Henrik Imberg; Sofia Dahlqvist; David Klonoff; Börje Haraldsson; J Hans DeVries; Marcus Lind
Journal:  J Diabetes Sci Technol       Date:  2016-06-28

3.  Delay discounting associated with challenges to treatment adherence and glycemic control in young adults with type 1 diabetes.

Authors:  Maria Stoianova; Elizabeth C Tampke; Amy Hughes Lansing; Catherine Stanger
Journal:  Behav Processes       Date:  2018-06-26       Impact factor: 1.777

4.  Explaining the increased mortality in type 1 diabetes.

Authors:  Chiara Mameli; Sara Mazzantini; Moufida Ben Nasr; Paolo Fiorina; Andrea E Scaramuzza; Gian Vincenzo Zuccotti
Journal:  World J Diabetes       Date:  2015-07-10

Review 5.  Islet Transplantation Alone Versus Solitary Pancreas Transplantation: an Outcome-Driven Choice?

Authors:  Paola Maffi; Antonio Secchi
Journal:  Curr Diab Rep       Date:  2019-04-25       Impact factor: 4.810

6.  Management of Hypertension and High Low-Density Lipoprotein in Pediatric Type 1 Diabetes.

Authors:  Michelle L Katz; Zijing Guo; Lori M Laffel
Journal:  J Pediatr       Date:  2018-02-01       Impact factor: 4.406

Review 7.  Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.

Authors:  Bernadette Biondi; George J Kahaly; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

8.  Proinsulin C-peptide is an autoantigen in people with type 1 diabetes.

Authors:  Michelle So; Colleen M Elso; Eleonora Tresoldi; Miha Pakusch; Vimukthi Pathiraja; John M Wentworth; Leonard C Harrison; Balasubramanian Krishnamurthy; Helen E Thomas; Christine Rodda; Fergus J Cameron; Jacinta McMahon; Thomas W H Kay; Stuart I Mannering
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

9.  [Diabetic nephropathy: current diagnostics and treatment].

Authors:  S Werth; H Lehnert; J Steinhoff
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

10.  Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes.

Authors:  Michael R Rickels; Amy J Peleckis; Eileen Markmann; Cornelia Dalton-Bakes; Stephanie M Kong; Karen L Teff; Ali Naji
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.